Pfizer: ‘Don’t be catfished by counterfeit drugs’
Pfizer UK has launched a new social media campaign urging people not to be “catfished” into buying counterfeit drugs.
Alexion Pharma to acquire Achillion for $930m
Alexion Pharmaceuticals is to acquire immune-system specialist Achillion for almost $1 billion dollars.
Brexit damaging UK life sciences talent and funding: The Royal Society
Brexit uncertainty is already having a negative impact on UK science, according to The Royal Society, the UK’s national academy of sciences.
LSPN 19: AI ‘explosion’ and drug costs in Canada
Uncertainty surrounding the patentability of artificial intelligence (AI) and changes to patented medicine pricing in Canada were two topics discussed yesterday, October 15 at Life Sciences Patent Network Fall in San Francisco.
UPL ordered to pay AgroFresh $31m for trade secrets theft
Indian chemical manufacturer UPL has been ordered to pay US-based AgroFresh Solutions $31 million after a jury ruled that it had stolen the company’s trade secrets and infringed one of its patents.
Philippines IP office issues warning over fake drugs
The Philippines’ deputy IP chief has warned e-commerce platforms that they could be made liable for the sale of counterfeit goods on their sites under new legislation, amid fears over the spread of counterfeit pharmaceuticals.
Qrons licenses 3D printing tech from Dartmouth Uni
US biotechnology company Qrons has obtained a world exclusive licence for IP related to 3D printable materials in the fields of human and animal health from Dartmouth University.
UCB to acquire Ra Pharmaceuticals in $2bn deal
Belgium head-quartered pharmaceutical company UCB is to acquire Ra Pharmaceuticals for approximately $2.1 billion.
Fed Circuit rules against Actavis knee pain generic
Actavis Laboratories cannot market a generic version of Horizon Pharma’s knee pain treatment, an appeals court has ruled.
Insilico Medicine signs $200m AI drug discovery deal
Hong Kong-based Insilico Medicine has agreed an artificial intelligence breast cancer drug discovery partnership worth a potential $200 million with a Chinese pharmaceutical company.
